-

QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on its website

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: https://corporate.qiagen.com/investor-relations/financial-reports/other-reports

QIAGEN N.V. further announced today that it had posted its 2019 Financial Report on its website at http://financialreport.qiagen.com

QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2019, was filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2020, a copy of which can be found on the website of the SEC at www.sec.gov or in the “Financial Information” section of the “Investors” section of our website at http://www.qiagen.com/About-Us/Investors/

QIAGEN will provide printed copies of the 2019 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2019 Annual Report please contact: IR@qiagen.com.

Please find the full press release here

Contacts

QIAGEN

Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Industry:

QIAGEN N.V.

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on Its website
Release Versions
English
$Cashtags
$QGEN
$QIA

Contacts

QIAGEN

Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Social Media Profiles
QIAGEN Facebook
More News From QIAGEN N.V.

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 3...

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,...

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...
Back to Newsroom